a) goes out and tries to raise capital. Share price is already #$%$. Good look without severely diluting the stock.
b) Sells parts of the company. ImmunAid and Rare Collect need to be the first to go.
c) Merger or sell the company. Shareholders will not be happy with a buyout of $3 a share. But it beats 0.
d) try to ride it out and see if they can get some more licensing to fund Brevagen for a couple quarters until it becomes profitable (if it ever does).